Reality check for device-drug convergence

Article Abstract:

The medical device industry is excited about the notion of drug-device convergence technology, which would impact the world of biology and engineering related to health care products and drugs. Some of the early convergence products, which have attained multi-billion-dollar sales in just over three years, include first-generation 'soft devices' that use an artificial matrix to deliver regenerative proteins.

Market share, Medical Instruments and Supplies, Medical Equipment and Supplies Manufacturing, Medical Instruments & Supplies, Technology application, Medical equipment and supplies industry, Medical equipment industry, Company market share, Medical test kit industry

---

A turbulent year at the agency

Article Abstract:

The year 2005 was the most politically charged year by all accounts in recent memory at the United States Food and Drug Administration (FDA). The fundamentals of reviewing drugs for approval started, by all accounts without any slowdown in the overall development and approval with FDA approving its stamp on eight biotech drugs in 2006, in line with the number from the past few years.

Forecasts, trends, outlooks, Management dynamics, Management, Forecasts and trends, Market trend/market analysis, Company business management, Drug approval

---

Looking for solid ground along the critical path

Article Abstract:

The Food and Drug Administration has entered into a partnership with Arizona-based Critical Path Institute (C-Path) to develop new tools to promote drug safety and accelerate drug developments. A profile of C-Path, which boost of success in initiating the warfarin program and the first Preclinical Safety Testing Consortium, is presented.

Alliances, partnerships, SOCIAL SERVICES, Social Assistance, Religious, Grantmaking, Civic, Professional, and Similar Organizations, Nonprofit Institutions, Social Services & Nonprofit Institutns, Nonprofit organizations, Alliances and partnerships, Pharmaceutical research

Similar abstracts:

• Abstracts: Gaining confidence. Something to shout about...
• Abstracts: Publicity pecking order. Searching for a mission. Lobbying do's and dont's
• Abstracts: From the ground up. Going for the access and the analytics
• Abstracts: Biotechnology financing dilemmas and the role of special purpose entities. Keeping it real with investors

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.